OBJECTIVES: An online survey was conducted with neurologists to understand how they assess multiple sclerosis (MS) during typical office visits.  This information was gathered to support the possible development of outcome measures for patients with MS. METHODS: A web-based survey was conducted with neurologists in the United States (US), United Kingdom (UK), Germany, and Sweden in April and May 2015.  The survey asked about neurologists’ professional background; perceptions of important symptoms and impact; and assessment methods used for each domain. RESULTS: A total of 72 neurologists (26 US; 25 UK; 11 Germany; 10 Sweden) completed the survey, including general neurologists (n=19; 26.4%) and neurologists specializing in MS (n=53; 73.6%).  The following signs/symptoms of MS were considered important to assess in every or most office visits by ≥75% of the sample: walking/gait issues (87.%), fatigue/exhaustion/tiredness (81.9%), pain (80.6%), bladder (79.2%), coordination (79.2%), weakness (79.2%), balance (77.8%), vision (77.8%), cognition (77.8%), spasticity (77.8%), and mood/emotions (75.0%).  Areas of impact most commonly identified as important to assess during office visits included mobility (91.7%), activities of daily living (84.7%), independence (84.7%), work (84.7%), self-care (77.8%), sleep (76.4%), and social functioning (75.0%).  Across all signs, symptoms, and areas of impact, the most common assessment approaches were asking the patient a direct question, the neurological exam, and informal observation of the patient.  Performance-based measures were used less frequently, most commonly to assess walking (by 23.6% of the sample).  Standardized clinician-reported (ClinRO) and patient-reported outcomes (PRO) instruments appear to be used rarely, but most commonly for assessment of cognition (12.5%). CONCLUSIONS: Neurologists reported that MS symptoms are typically assessed via general questions, a neurological exam, and direct observation.  According to this sample, standardized measurement approaches are not commonly used.  A brief clinician-reported measure of MS symptoms and impact could help standardize and quantify these assessments.